| Overview |
| bs-11541R-Cy5 |
| Calcipressin 1/DSCR 1 Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Calcipressin 1 |
| 101-200/252 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cytoplasm, Nucleus |
| Adapt 78; Adapt78; Calcipressin 1; Calcipressin-1; Calcium and oxidant inducible mRNA; CSP 1; CSP1; Down syndrome candidate region 1; Down syndrome critical region gene 1; Down syndrome critical region protein 1; DSC 1; DSC1; DSCR 1; DSCR1; DSCR-1; MCIP 1; MCIP1; Modulatory calcineurin interacting protein 1; Myocyte enriched calcineurin interacting protein 1; Myocyte-enriched calcineurin-interacting protein 1; Near DSCR proline rich protein; RCAN1; RCAN1_HUMAN; RCN 1; RCN1; Regulator of calcineurin 1. |
| DSCR1 protein influences cardiac and nervous system development (1). DSCR1 is abundant in the brain, heart, and skeletal muscle. Overexpression of DSCR1 may play a role in the pathogenesis of Down syndrome, in particular mental retardation and/or cardiac defects. DSCR1 inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A. Human DSCR1 maps to gene locus 21q22.1-q22.2. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz